Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
By T. Witzig, I. Flinn, L. Gordon, C. Emmanouilides, M. Czuczman, M. Saleh, L. Cripe, G. Wiseman, T. Olejnik, P. Multani and 1 more. Journal of Clinical Oncology, 2002
650 citations recorded by the source corpus.
Subfields: Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/09ca3ace4f315bbcfba63812e43ff87e643f1329
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance (2003, background): “In patients refractory to rituximab, overall response rate to the radioimmunotherapy was similar to that of patients who had not previously received rituximab (Witzig et al., 2002a).”